Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

ResMed Inc. (RMD.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
33.55-1.07 (-3.09%)
At close: 04:10PM AEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close34.62
Open33.29
Bid33.51 x 51100
Ask33.86 x 25600
Day's Range32.59 - 33.88
52 Week Range27.37 - 40.79
Volume1,275,270
Avg. Volume1,260,550
Market Cap49.652B
Beta (5Y Monthly)0.47
PE Ratio (TTM)43.57
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.24 (0.69%)
Ex-Dividend DateMay 11, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for RMD.AX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Benzinga

      Competitor Recall Continues To Show Opportunities For ResMed

      ResMed Inc (NYSE: RMD) posted Q4 sales of $914.7 million, +4% Y/Y (+8% on a constant currency basis), beating the consensus of $912.97 million. Adjusted EPS reached $1.49, up from $1.35 a year ago. The company also increased its quarterly dividend to $0.44 from $0.42 per share. Keybanc reiterates the Overweight rating and price target of $276. The analyst says that after resetting near-term supply chain expectations, visibility appears to be increasing and management's tone seemed more optimisti

    • Zacks

      ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up

      ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.

    • Motley Fool

      ResMed (RMD) Q4 2022 Earnings Call Transcript

      Joining me on the call today are our chief executive officer, Mick Farrell, and chief financial officer, Brett Sandercock. Following our prepared remarks, we will host a Q&A session, and Mick and Brett will be joined by Rob Douglas, president and chief operating officer, and David Pendarvis, chief administrative officer and global general counsel.

    Advertisement
    Advertisement